Neuroone Medical Technologies Corp (NMTC) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Neuroone Medical Technologies Corp stock $0.61, price $0.88, that is 30.4% below the price, quality 49 out of 100. Rating: overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.
How to read this chart
60‑month range $0.8039 – $32.46 · fair‑value band $0.3995 – $0.7565 · the $0.8790 price screens above the $0.6120 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.
Follow Neuroone Medical Technologies in your weekly email
Every Wednesday you see whether Neuroone Medical Technologies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
NeuroOne Medical Technologies Corporation, a medical technology company, provides solutions for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording in the United States.
Show moreShow less
The company also provides solutions for spinal cord stimulation, brain stimulation, drug delivery and ablation solutions for patients suffering from epilepsy, trigeminal neuralgia, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other pain-related neurological disorders.
The company has a collaboration with the Department of Neurology's Division of Epilepsy at the University of Minnesota Medical School to advance a study evaluating epilepsy therapies. The company is based in Eden Prairie, Minnesota.
Stock analysis
Neuroone Medical Technologies Corp (NMTC) currently trades at $0.8790, while our model-based Fair Value estimate is $0.6120, 30% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $0.3995 (bear) to $0.7565 (bull), the price of $0.8790 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Neuroone Medical Technologies Corp reported revenue of $12.1M in FY2025 versus $178K in FY2021, a compound +187.1%/yr. Reported net income was −$3.6M in FY2025.
Key figures
Market cap $7.7M Micro · P/S ratio 0.63 · EPS (TTM) $−1.02 · Net margin −59.7% · Return on equity −125% · Return on assets (EBIT) −123% (5-year average) · Operating margin −123% · Revenue (TTM) $12.5M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).
What moves the price
The share trades about 85% below its 52-week high and 9% above its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −30%, NMTC screens richer than that median.
Fair Value models
Bear$0.3995Fair Value $0.6120Bull$0.7565
Price $0.8790 · Downside -30.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham)$0.4700$0.7200$0.890055
All 1 models by family
Asset-Based
NCAV (Graham)$0.4700$0.7200$0.890055
The fair value above starts from this blend and is adjusted for dilution from new shares.
In the last 6 months, one officer or director bought shares worth $66,999, on Aug 27, 2026. Over the same period, one person sold shares worth $31,800.
BuyDavid J. WambekeChief Business Officer2× since Mar 1, 2026: 1,033,333 shares, avg. $0.7132$736,999Aug 27, 2026
SaleMark ChristiansonMarket Development Director4× since Mar 10, 2026: 40,000 shares, avg. $1.37$54,878Jun 30, 2026
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.34/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+250.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+313.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+44.4%
Start year 2020 (pandemic). Over 10 years: +162.7% a year
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+85.2%
’11
’12
’13
’14
’15
’16
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−254.5% (2020) → −34.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Neuroone Medical Technologies Corp with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 319 stocks
Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score49 · Below median
Fair Value upside−30.4% · Below median
Profitability
Return on assets−33.4% · Bottom 25%
Net margin (12 months)−59.7% · Bottom 25%
Operating margin (12 months)−122.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)16.3% · Above median
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/B1.09× · Cheaper than median
P/S (12 months)0.62× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 6
FUTURE (revenue growth)82· sector 36
PAST (return on equity)0· sector 17
HEALTH (low debt)100· sector 98
DIVIDEND (yield)0· sector 34
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Neuroone Medical Technologies Corp Fair Value". https://www.fairvalue-calculator.com/stock/NMTC
Frequently asked questions
Is Neuroone Medical Technologies Corp (NMTC) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of $0.6120 versus a price of $0.8790, about 30% lower (overvalued).
What is the fair value of NMTC?
Our model-based fair value for Neuroone Medical Technologies Corp is $0.6120 (as of Nov 4, 2026), built from audited fundamentals. The current price: $0.8790.
What is the quality score of NMTC?
Neuroone Medical Technologies Corp has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Neuroone Medical Technologies Corp (NMTC)?
Our model-based price target is the fair value of $0.6120 (as of Nov 4, 2026) from 1 valuation models. Cautious scenario $0.3995, optimistic scenario $0.7565. It is a calculation from audited fundamentals, not an analyst target.
What is the Neuroone Medical Technologies Corp stock forecast for 2026?
Our models put fair value at $0.6120, about 30% lower versus a price of $0.8790 (overvalued). Cautious scenario $0.3995, optimistic scenario $0.7565. The calculation is refreshed regularly with new filings.
What is the revenue of Neuroone Medical Technologies Corp (NMTC)?
Neuroone Medical Technologies Corp reported trailing-twelve-month revenue of about $12.5M (latest available figure, as of Nov 4, 2026).
What is the intrinsic value of Neuroone Medical Technologies Corp (NMTC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Neuroone Medical Technologies Corp it is $0.6120 per share (as of Nov 4, 2026), against a price of $0.8790. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Neuroone Medical Technologies Corp stock overvalued or undervalued in 2026?
As of Nov 4, 2026, NMTC trades above its calculated fair value: price $0.8790, fair value $0.6120, a gap of about −30% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NMTC?
No. The price is what the market pays today ($0.8790); the fair value is what the company's own numbers justify ($0.6120). For Neuroone Medical Technologies Corp the two are $0.2670 per share apart. That gap is exactly why we show both numbers side by side.
How much is Neuroone Medical Technologies Corp worth?
The market values Neuroone Medical Technologies Corp at about $7.7M (market capitalisation, as of Nov 4, 2026). Per share that is $0.8790; our models calculate a fair value of $0.6120 per share.
What do the bullish and bearish scenarios say about NMTC?
Our models span a range for Neuroone Medical Technologies Corp: cautious scenario $0.3995, base $0.6120, optimistic $0.7565 per share (as of Nov 4, 2026, price $0.8790). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Neuroone Medical Technologies Corp (NMTC)?
Balance-sheet figures for Neuroone Medical Technologies Corp (as of Nov 4, 2026): return on equity −124.7%. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is NMTC from its 52-week high?
Neuroone Medical Technologies Corp trades at $0.8790, about 85% below its 52-week high of $5.89 and 9% above the low of $0.8039 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $0.6120 is for.
Which stocks are comparable to Neuroone Medical Technologies Corp?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Neuroone Medical Technologies Corp stock attractive at the current price?
The data as of Nov 4, 2026: price $0.8790, calculated fair value $0.6120 (−30%), Quality Score 49/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NMTC calculated?
We run Neuroone Medical Technologies Corp through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $0.6120 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Neuroone Medical Technologies Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Neuroone Medical Technologies Corp (NMTC)?
The closing price on Nov 6, 2026 was $0.8790. Our model-based fair value is $0.6120, about 30% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Neuroone Medical Technologies Corp right now?
The price sits above even our optimistic bull case ($0.7565). The favourable scenario is already priced in. Weak quality (49/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.3995 to $0.7565) leaves room in how you read the outcome.
Key figures of Neuroone Medical Technologies Corp
How large is the market capitalisation of Neuroone Medical Technologies Corp (NMTC)?
The market capitalisation of Neuroone Medical Technologies Corp is $7.7M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Neuroone Medical Technologies Corp (NMTC)?
The price-to-sales ratio of Neuroone Medical Technologies Corp is 0.63 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Neuroone Medical Technologies Corp (NMTC)?
Earnings per share at Neuroone Medical Technologies Corp are $−1.02. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Neuroone Medical Technologies Corp (NMTC)?
The net margin of Neuroone Medical Technologies Corp is −59.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Neuroone Medical Technologies Corp (NMTC)?
The return on equity (ROE) of Neuroone Medical Technologies Corp is −125% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Neuroone Medical Technologies Corp (NMTC)?
On an EBIT basis the return on assets of Neuroone Medical Technologies Corp is −123% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Neuroone Medical Technologies Corp (NMTC)?
The operating margin of Neuroone Medical Technologies Corp is −123% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Neuroone Medical Technologies Corp (NMTC)?
Revenue at Neuroone Medical Technologies Corp is growing +16.3% versus a year earlier (3y avg +313%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Neuroone Medical Technologies Corp (NMTC) generate?
The free cash flow of Neuroone Medical Technologies Corp is −$2.9M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Neuroone Medical Technologies Corp (NMTC) hold?
Neuroone Medical Technologies Corp holds more cash than debt, $6.3M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Neuroone Medical Technologies Corp in the live analysis
One click puts Neuroone Medical Technologies Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 4, 2026
